Pulmonary hypertension resident survival guide: Difference between revisions
No edit summary |
|||
Line 26: | Line 26: | ||
{{familytree | | | | A01 | | | | | |A01=<div style="float: left; text-align: left; line-height: 150% "> '''Characterize the symptoms:''' <br> ❑ Progressive [[dyspnea]] <br> ❑ Exertional [[dizziness]] and [[syncope]] <br> ❑ [[Edema]] of the extremities <br> ❑ [[Angina]] <br> ❑ [[Palpitation]]s </div>}} | {{familytree | | | | A01 | | | | | |A01=<div style="float: left; text-align: left; line-height: 150% "> '''Characterize the symptoms:''' <br> ❑ Progressive [[dyspnea]] <br> ❑ Exertional [[dizziness]] and [[syncope]] <br> ❑ [[Edema]] of the extremities <br> ❑ [[Angina]] <br> ❑ [[Palpitation]]s </div>}} | ||
{{familytree | | | | |!| | | | | | | }} | {{familytree | | | | |!| | | | | | | }} | ||
{{familytree | | | | B01 | | | | | |B01=<div style="float: left; text-align: left; line-height: 150% "> '''Examine the patient:''' <br> ❑ Loud pulmonary second heart sound (P2) <br> ❑ [[Systolic murmur]] suggestive of [[tricuspid regurgitation]] <br> ❑ Raised [[JVP|jugular venous pressure]] (JVP) <br> ❑ | {{familytree | | | | B01 | | | | | |B01=<div style="float: left; text-align: left; line-height: 150% "> '''Examine the patient:''' <br> Physical signs that reflect severity of PH <br> ❑ Loud pulmonary second heart sound (P2) <br> ❑ [[Systolic murmur]] suggestive of [[tricuspid regurgitation]] <br> ❑ Raised [[JVP|jugular venous pressure]] (JVP) <br> ❑ Early systolic click <br> ❑ Left parasternal heave <br> ❑ Right ventricular S<sub>4</sub> | ||
---- | |||
Physical signs suggestive of moderate to severe PH <br> ❑ Holosystolic murmur that increases with inspiration <br> ❑ Increased jugular v waves <br> ❑ Pulsatile liver <br> ❑ Diastolic murmur <br> ❑ Hepatojugular relux | |||
---- | |||
Physical signs suggestive of advanced PH with right ventricular failure <br> ❑ Right ventricular S<sub>3</sub> <br> ❑ Distension of jugular veins <br> ❑ Hepatomegaly <br> ❑ Peripheral edema <br> ❑ Ascites <br> ❑ Low BP, cool extremities | |||
---- | |||
Physical signs suggestive of possible underlying causes <br> ❑ Central cyanosis - Abnormal V/Q, shunt <br> ❑ Clubbing - Congenital heart disease <br> ❑ Cardiac auscultatory findings - Congenital or acquired heart disease <br> ❑ Rales/decreased breath sounds/dullness - Pulmonary congestion<br> ❑ Fine rales, acc. muscle use, wheezing, protracted respiration, cough - Pulmonary parenchymal disease <br> ❑ Obesity, kyphoscoliosis, enlarged tonsils - Disordered ventilation <br> ❑ Sclerodactyly, arthritis, telengiectasia, Raynaud phenomenon, rash - Connective tissue disorder <br> ❑ Peripheral venous insufficiency - Possible venous thrombosis <br> ❑ Venous stasis ulcers - Possible sickle cell disease <br> ❑ Pulmonary vascular bruits - Chronic thromboembolic PH <br> ❑ Splenomegaly, spider angiomata, palmar erythema, icterus, caput medusa - portal hypertension | |||
{{familytree | | | | |!| | | | | | | }} | {{familytree | | | | |!| | | | | | | }} | ||
{{familytree | | | | C01 | | | | | |C01=<div style="float: left; text-align: left; line-height: 150% "> '''Consider alternative diagnosis:''' <br> ❑ [[Left sided heart failure]] <br> ❑ [[Coronary artery disease]] <br> ❑ [[Liver|Liver disease]] <br> ❑ [[Budd-Chiari syndrome]] | {{familytree | | | | C01 | | | | | |C01=<div style="float: left; text-align: left; line-height: 150% "> '''Consider alternative diagnosis:''' <br> ❑ [[Left sided heart failure]] <br> ❑ [[Coronary artery disease]] <br> ❑ [[Liver|Liver disease]] <br> ❑ [[Budd-Chiari syndrome]] |
Revision as of 18:06, 9 January 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: , Vidit Bhargava, M.B.B.S [2]
Definition
Pulmonary hypertension (PH) is defined by mean pulmonary artery pressure > 25, pulmonary capillary wedge pressure (PCWP), left atrial pressure, or left ventricular end-diastolic pressure (LVEDP) ≤ 15 mm Hg; and a pulmonary vascular resistance (PVR) > than 3 Wood units. [1]
Causes
Life Threatening Causes
Life-threatening causes include conditions which may result in death or permanent disability within 24 hours if left untreated.
Common Causes
- Congenital heart disease with left-to-right shunt (ASD, VSD, PDA)
- Congestive heart failure
- COPD
- Cor pulmonale
- Interstital lung disease
- Obstructive sleep apnea
- Thromboembolism
Management
{{familytree | | | | B01 | | | | | |B01=Physical signs that reflect severity of PH
❑ Loud pulmonary second heart sound (P2)
❑ Systolic murmur suggestive of tricuspid regurgitation
❑ Raised jugular venous pressure (JVP)
❑ Early systolic click
❑ Left parasternal heave
❑ Right ventricular S4
Physical signs suggestive of moderate to severe PH
❑ Holosystolic murmur that increases with inspiration
❑ Increased jugular v waves
❑ Pulsatile liver
❑ Diastolic murmur
❑ Hepatojugular relux
Physical signs suggestive of advanced PH with right ventricular failure
❑ Right ventricular S3
❑ Distension of jugular veins
❑ Hepatomegaly
❑ Peripheral edema
❑ Ascites
❑ Low BP, cool extremities
Physical signs suggestive of possible underlying causes
❑ Central cyanosis - Abnormal V/Q, shunt
❑ Clubbing - Congenital heart disease
❑ Cardiac auscultatory findings - Congenital or acquired heart disease
❑ Rales/decreased breath sounds/dullness - Pulmonary congestion
❑ Fine rales, acc. muscle use, wheezing, protracted respiration, cough - Pulmonary parenchymal disease
❑ Obesity, kyphoscoliosis, enlarged tonsils - Disordered ventilation
❑ Sclerodactyly, arthritis, telengiectasia, Raynaud phenomenon, rash - Connective tissue disorder
❑ Peripheral venous insufficiency - Possible venous thrombosis
❑ Venous stasis ulcers - Possible sickle cell disease
❑ Pulmonary vascular bruits - Chronic thromboembolic PH
❑ Splenomegaly, spider angiomata, palmar erythema, icterus, caput medusa - portal hypertension
Consider alternative diagnosis: ❑ Left sided heart failure ❑ Coronary artery disease ❑ Liver disease ❑ Budd-Chiari syndrome | |||||||||||||||||||||||||||
Acute vasoreactivity testing | |||||||||||||||||||||||||||
Positive | Negative | ||||||||||||||||||||||||||
Oral calcium channel blocker (CCB) | Lower risk | Higher risk | |||||||||||||||||||||||||
❑ Follow closely for efficacy and safety Sustained response | ❑ Endothelin receptor antagonsists (ERA's) or Phospodiesterase-5 inhibitors (PDE-5 Is) (oral) ❑ Epoprostenol or Treprostinil (IV) ❑ Iloprost (inhaled) ❑ Treprostinil (SC) | ||||||||||||||||||||||||||
❑ Reassess | |||||||||||||||||||||||||||
Continue CCB | In case of absence of response to initial monotherapy: ❑ Consider combo-therapy | ||||||||||||||||||||||||||
In case of progress despite optimal medical treatment: ❑ Investigational protocols, OR ❑ Atrial septostomy, OR ❑ Lung transplant | |||||||||||||||||||||||||||
The following guideline is based on Expert consensus document on pulmonary hypertension published by ACCF/AHA in 2009.[2]
Follow up testing after etiology for pulmonary hypertension is established:
Substrate | Futher action |
---|---|
BMPR2 mutation 1st degree relative of patient with BMPR2 mutation or with 2 or more relatives with PH |
❑ Yearly echocardiogram, right heart catheterization if evidence of PH. ❑ Genetic counselling for BMPR2 testing, proceed as aboveif positive. |
Systemic sclerosis | ❑ Yearly echocardiogram, right heart catheterization if evidence of PH. |
HIV infection | Do echocardiogram if signs & symptoms are suggestive of PH. Right heart catheterization if evidence of PH on echo. |
Portal hypertension | ❑ If considering orthotopic liver transplant perform echocardiogram. ❑ Right heart catheterization if evidence of PH. |
CHD with shunt | ❑ Echocardiogram and right heart catheterization at the time of diagnosis. ❑ If significant defect - repair. |
Recent acute pulmonary embolism | ❑ If symptomatic 3 months after event, perform ventilation perfusion scinitigraphy. ❑ Do a pulmonary angiogram if positive. |
Prior appetite suppressant use (fenfluramine) | ❑ Echocardiogram only if symptomatic. |
Sickle cell disease | ❑ Yearly echocardiogram, right heart catheterization if evidence of PH. |
Do's
- The diagnosis of Pulmonary hypertension requires confirmation with a right heart catheterization.
- Objective assessment of treatment measures includes:
- Exercise capacity.
- Hemodynamics.
- Survival.
- Epoprostenol is the only therapy that has been shown to prolong survival in patients with pulmonary hypertension.
- Monitor liver function tests monthly in patients being treated with endothelin receptor antagonists.
- Patients presenting with advanced symptoms, right heart failure, advanced hemodynamics and those on parenteral or combination therapy must be seen every 3 months.
Don'ts
- Do not perform vasospastic testing for those with overt heart failure or hemodynamic instability.
References
- ↑ Kiely, DG.; Elliot, CA.; Sabroe, I.; Condliffe, R. (2013). "Pulmonary hypertension: diagnosis and management". BMJ. 346: f2028. PMID 23592451.
- ↑ McLaughlin VV, Archer SL, Badesch DB, Barst RJ, Farber HW, Lindner JR; et al. (2009). "ACCF/AHA 2009 expert consensus document on pulmonary hypertension: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association: developed in collaboration with the American College of Chest Physicians, American Thoracic Society, Inc., and the Pulmonary Hypertension Association". Circulation. 119 (16): 2250–94. doi:10.1161/CIRCULATIONAHA.109.192230. PMID 19332472.